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Background: The hereditary spastic paraplegias (HSPs) are pleiomorphic disorders of motor pathway and a large
number of affected genes have been discovered. Yet, mutations in SPG4/SPAST represent the most frequent
molecular etiology in autosomal dominant (AD) patients and sporadic cases. We describe a large, AD-HSP Sardinian
family where 5 out of several living members harbored a novel deletion affecting also the 5′UTR of SPAST and
resulting in reduced expression of DPY30, the gene located upstream SPAST in a head-to-head manner.
Case presentation: A 54-year-old woman manifested leg stiffness at age 39 and required a cane to walk at age 50.
Neurological examination disclosed mild spasticity and weakness in the legs, hyperreflexia in all limbs, and bilateral
Babinski sign. She also complained of urinary urgency, but no additional neurological symptoms or signs were
detected at examination. The clinical examination of 24 additional relatives disclosed three further affected
individuals, two men and one woman. In the four symptomatic patients the initial manifestations were walking
abnormalities and leg stiffness with a mean age at onset (SD) of 46.75 (5.44) years (range 39–51). The mean disease
duration was 13.2 (13.4) years (range 6–35), and it correlated well with clinical severity (SPRS score) (r = 0.975, p =
0.005). One patient was confined to bed and displayed knee and ankle contractures, another case needed a cane to
walk, and two individuals were able to walk without aids. Interestingly, a patient had also had a miscarriage during
her first pregnancy.
Gene testing revealed an heterozygous deletion spanning from the 5′-UTR to intron 4 of SPAST in the affected
individuals and in one clinically unaffected woman. In three affected patients, the deletion also determined low
mRNA levels of SPAST and DPY30, a component of the Set1-like multiprotein histone methyltransferase complex
located upstream, head-to-head with SPAST.
Conclusion: Together with data described in a Japanese family, our findings seem to suggest that genes close to
spastin might be candidates in modulating the clinical phenotype. This report endorses future research on the role
of neighboring genes as potential players in SPG4 disease variability.
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Heterogeneity is a key feature of the hereditary spastic
paraplegias (HSPs). To date, autosomal, sex-linked, and
cytoplasmic inheritance have been reported, an ample
array of complicated phenotypes disclosed, more than 70
loci mapped, and roughly 50 disease genes cloned [1,2].
In common clinical practice, the gene-after-gene testing
strategy allows definition of the molecular basis in about
half of HSP cases, unless peculiar features emerge during
examination or follow-up.* Correspondence: filippo3364@gmail.com
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unless otherwise stated.Mutations in SPAST/SPG4 encoding spastin represent
the most common cause of autosomal dominant heredi-
tary spastic paraplegias (AD-HSP) and also account for
about 15% of sporadic cases [3,4]. In north-west Sardinia
the relative frequency of HSP is higher than what is cal-
culated in other Western European populations with an
estimated crude prevalence of about 17.5/100,000 for
AD-HSP [5]. As documented in several families and dif-
ferent populations [4,6], the SPG4 phenotype is usually
pure and inter- and intra-familial variability of the clin-
ical presentation are well established [7]. In some cases,
single nucleotide polymorphisms in SPAST and variantsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Racis et al. BMC Medical Genetics 2014, 15:39 Page 2 of 5
http://www.biomedcentral.com/1471-2350/15/39in additional genes are invoked as modifiers of age at
onset, disease course and severity [8,9].
We identified a novel SPAST mutation segregating in a
Sardinian kindred (family IK).Case presentation
The proband, a 54-year-old woman (IV-13) (Figure 1),
manifested leg stiffness at age 39 and required a cane to
walk at age 50. Neurological examination disclosed mild
spasticity and weakness in the legs, enhanced deep ten-
don reflexes in all limbs, and bilateral Babinski sign.
Case IV-13 also complained of urinary urgency, but no
additional neurological symptoms or signs were detected
at examination. The patient reported that her deceased
father (III-03) and two uncles (III-02, III-04) had mani-
fested similar gait abnormalities in adult age, although
with different degree. Detailed clinical information and
examinations were gathered from her living relatives.Figure 1 (Top) Family pedigree. The arrow indicates the index case. Squa
individuals; empty symbols show clinically healthy relatives. Carriers of the
symbols indicate individuals who underwent DNA studies but then tested
c.1-763_c.683-650del affecting the 5′UTR and exons 1–4 of SPAST, and theMaterials and methods
Total genomic DNA was purified by peripheral blood
with standard methodologies. Analysis of common AD
genes associated with HSP used traditional Sanger se-
quencing and the BigDye 3.1 Chemistry, as reported [5].
Search for copy number variation and gene deletion/du-
plication adopted reported array-comparative genomic
hybridization (aCGH) and multiple ligation-dependent
probe amplication (MLPA) methodologies [10].
Twenty-four additional relatives were examined and
sampled with written informed consent in family IK.
Using oligonucleotide primers (5′-3′) SPASTPrimer F,
SPASTPrimer R1 and SPASTPrimer R2 that were de-
signed flanking the mutation deletion breakpoints (se-
quences available upon request), we PCR-amplified
genomic DNA to generate a single 955-bp fragment in
wild-type individuals. The presence of the heterozygous
SPAST deletion produced an additional fragment of 303-
bp (Figure 2).res, men; Circles, women. Black symbols indicate clinically affected
novel mutation in SPG4/SPAST are indicated with a dotted frame. Star
normal. (Bottom) Electropherogram flanking the novel mutation
position of spastin neighboring genes.
Figure 2 Rapid diagnostic genotyping of the multi-exon deletion detected in the IK family by a duplex-PCR method.
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tion deletion in SPAST, total blood RNA was extracted
using a micro-scale total RNA separator kit (Ambion
INC., Austin, TX). For standard gene expression experi-
ments, the mRNA transcript levels were determined by
qPCR runs in an ABI7500Fast system (Applied Biosys-
tems, Foster City, CA) using the TaqMan Universal PCR
Protocol, and human SPAST (Hs00368084_m1, Applied
Biosystems), SLC30A6 (Hs01071782_m1), and DPY30
(Hs00261491_m1) as probes. GAPDH (Hs99999905_m1,
Applied Biosystems) was used for endogenous normaliza-
tion, and expressions were determined using the compara-
tive Ct method [11]. Values were normalized in reference
to the average control value obtained from three age-
matched normal control subjects. Statistical analyses used
unpaired two-tailed Student-test (significance was set at
p <0.05).
Results
No point mutations were found in SPAST and analyses
of other frequent AD-HSP etiologies (namely, SPG3A/
ATL1, SPG31/REEP1, SPG10/KIF5A, SPG8/KIAA0196)
were all normal in the proband. Combination of custom-
ized aCGH, MLPA analysis, and direct sequencing identi-
fied a novel heterozygous mutation (c.1-763_c.683-650del)
spanning 51 kb, from the 5′-UTR (and upstream regula-
tory elements) to intron 4 of SPAST. The deletion mutation
was not found in the NCBI genomic structural variations
database (http://www.ncbi.nlm.nih.gov/dbvar/?term=human
+SPAST) nor in polymorphic databases.
Using a rapid PCR-based method to quickly genotype
individuals in the family, and rule out the mutation in 500
ethnically-matched control chromosomes, we identifiedthe new mutation in a total of five individuals, including
the yet asymptomatic IV-25 (Figure 1). In all, global dis-
ease severity was assessed using the Spastic Paraplegia
Rating Scale (SPRS) [12]. Table 1 summarizes clinical data
in carriers of the novel SPAST mutation deletion. In the
four symptomatic patients the initial manifestations were
walking abnormalities and leg stiffness with a mean age at
onset (SD) of 46.75 (5.44) years (range 39–51). The mean
disease duration was 13.2 (13.4) years (range 6–35).
Pearson’s correlation coefficient indicated a positive cor-
relation between disease duration and clinical severity
(SPRS score) (r = 0.975, p = 0.005). One patient (III-04)
was confined to bed and displayed knee and ankle con-
tractures, another needed a cane to walk, and two individ-
uals were able to walk without aids. Interestingly, subject
IV-07 had also had a miscarriage during her first preg-
nancy. At this point, we cannot state if IV-25 will develop
any clinical manifestation in the near future or if she is a
true not penetrant carrier of the mutation, since her
present age is slightly younger than the mean age of onset
of motor disturbances in the family. Reduced or no pene-
trance has repeatedly been described in spastin-related
HSP kindred [1,3], including cases from Sardinia [10].
In three affected patients, we observed that the dele-
tion also determined low mRNA levels of SPAST and
DPY30, a component of the Set1-like multiprotein his-
tone methyltransferase complex located upstream, head-
to-head with SPAST [15] (Figure 3).
Discussion
This report is the third description of a deletion charac-
terizing the 5′-UTR of SPAST. Interestingly, the muta-
tion also affected even more upstream sequences likely
Table 1 Clinical features in the five patients harboring the mutation in the IK family
III-04 IV-04 IV-07 IV-13 IV-25
Age/Sex 86/M 53/M 60/F 54/F 42/F
Age at Onset, yrs 51 47 50 39 NA
Disease duration, yrs 35 6 10 15 0
SPRS scorea 47 12 6 16 0
SPRS item 13b 4 1 1 1 0
Spasticity score LLc 4 2 1 2 0
Muscle strenght score LLd 0 5 4 4 5
Hyperreflexia UL/LL Contracture 0/+ + + 0/+ + +/+ + + 0/0
Babinski sign + + Indifferent + Indifferent
Decreased vibration sense na No No No No
EMG/NCS na/na Abnormal*/n n/n n/n na/na
Miscarriage/Pregnancy 1/3 0/0 0/1
M man, F woman, UL Upper Limbs, LL Lower Limbs, na not available, EMG electromyography, NCS nerve conduction studies, n Normal; *slight impairment but no
frank signs of denervation.
aThe SPRS score ranges from 0 (normal) to 52 (severely affected) [12]; b1 = Urinary urgency (difficulties to reach toilet in time); 4 = Permanent catheterization; cThe
Modified Ashworth Scale of Muscle Spasticity score ranges from 0 (no increase in tone) to 4 (affected parts rigid in flexion or extension) [13]; dThe Medical
Research Council Scale for Muscle Strength score ranges from 0 (no contraction) to 5 (normal strength) [14].
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ously, a deletion was found in a Japanese family with
clinical features and disease duration highly similar to
our cases [16]. Also, six men and four women in a fur-
ther Japanese kindred harbored a 70 kb deletion involv-
ing exons 1 to 4 of SPAST and also exons 1 to 3 of
DPY30 [17]. Those patients had on average a teenage
onset and a slowly progressive course leading to wheel-
chair in four, and use of a walking stick in one case.
Other clinical features in that family were mild cognitive
impairment and slight peripheral neuropathy. We be-
lieve that the presence of the spastin deletion might well
explain a tendency towards less severe walking disability
in family IK and in the Japanese kindred as described be-
fore in other families [3,9]. It is, however, intriguing that
all affected Japanese women experienced miscarriages of
unknown etiology similar to subject IV-07 in our kin-
dred. Whether the shared feature of birth interruption
relates to a similar defect in DPY30 is still questionable.Figure 3 Bar chart showing the relative expression of mRNA/SPAST, m
from three patients in the IK family (samples refer to pedigree in Figure 1)
determinations. Values are reported as the ratio to the internal control (GA
from three age-matched normal subjects (Ctrls). **, p < 0.01; *, p < 0.05.DPY30 is yet to be fully characterized but it seems to
be essential for neural fate of embryonic cells, cell-
cycling and cellular proliferation [15,18]. In nematodes,
null mutations in dpy-30 cause XX-specific lethality and
the gene is required for normal development of XO
males [19]. As it orthologue, it can be speculated that
human DPY30 is also implicated in brain development
and infertility [20] and when mutated might lead to mis-
carriages. The hypothetical function of the gene, how-
ever, cannot clearly explain how a low DPY30/mRNA
expression (probably because of a position effect involv-
ing long-range gene regulatory elements) in the IK fam-
ily with a milder phenotype agrees with the reduced
mRNA levels (because of partial gene deletion) in the
Japanese family with an earlier onset and apparently
more severe neurological features [17]. We have no
clear-cut explanation for this apparent “clinical riddle”
other than raising the possibility of additional modifiers
in the two families, maybe related to the different ethnicRNA/DPY30, and mRNA/SLC30A6 in blood. Data are presented
with error bars representing the mean ± SD of three different
PDH), and are also expressed in reference to the average control value
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tion of SLC30A6 — the gene flanking SPAST 3′UTR —
in another Italian SPG4 family [10], this report endorses
future research on the role of neighboring genes as po-
tential players in SPG4 disease variability.
Conclusion
We describe an AD-HSP Sardinian family where 5 out
of several living members harbored a novel deletion af-
fecting also the 5′UTR of SPAST and resulting in re-
duced expression of DPY30, the gene upstream SPAST
in a head-to-head manner. If the presence of the spastin
deletion might well explain a tendency towards less se-
vere walking disability in our family, it is intriguing that
a patient in our kindred experienced a miscarriage of
unknown etiology similar to all affected women in a Jap-
anese family harboring a SPAST and DPY30 deletion.
This report encourages future research on the role of
neighboring genes as potential players in SPG4 disease
variability.
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